Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is being used in an ever increasing number of tumors. A number of cardiovascular complications may limit its use.
Arterial thromboembolization includes:
(1) cerebral infarction or transient ischemic event
(2) angina or acute myocardial infarction
(3) infarction of other organs
Risk factors for arterial thromboembolism:
(1) age >= 65 years
(2) history of previous arterial thromboembolic event
The risk of arterial thromboembolism is reduced in persons taking aspirin.
where:
• Antiphospholipid syndrome is associated with arterial thrombosis.
• A history of a previous arterial thromboembolic event would include stroke and acute myocardial infarction.
• Other antiplatelet agents should also reduce the risk of arterial thromboemboli.
To read more or access our algorithms and calculators, please log in or register.
